Skip to main content
SpringerLink
Log in

Development: In Vivo Pharmacology—Systems Biology in Health and Disease II

  • Chapter
  • First Online:
Systems Biology in Biotech & Pharma

Part of the book series: SpringerBriefs in Pharmaceutical Science & Drug Development ((BRIEFSPSDD,volume 2))

  • 1055 Accesses

Abstract

This chapter covers qualitative in vivo approaches in animals and man, which will help to develop in silico pharmacology and PK positions. Additionally, we cover RNA interference in this chapter even though it is largely an in vitro method for characterizing the dynamics of cell physiology. And though in silico pharmacology is only in a rudimentary state, it is vitally important for clinical model based drug design (MBDD) development (see Chap. 10).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Brown SD, Hancock JM (2006) The mouse genome. Genome Dyn 2:33–45

    Article  PubMed  CAS  Google Scholar 

  2. Shultz LD, Ishikawa F, Greiner DL (2007) Humanized mice in translational biomedical research. Nat Rev Immunol 7(2):118–130

    Article  PubMed  CAS  Google Scholar 

  3. Gondo Y (2008) Trends in large-scale mouse mutagenesis: from genetics to functional genomics. Nat Rev Genet 9(10):803–810

    Article  PubMed  CAS  Google Scholar 

  4. Kissler S, Van Parijs L (2004) Exploring the genetic basis of disease using RNA interference. Expert Rev Mol Diagn 4(5):645–651

    Article  PubMed  CAS  Google Scholar 

  5. Lewandoski M (2001) Conditional control of gene expression in the mouse. Nat Rev Genet 2(10):743–755

    Article  PubMed  CAS  Google Scholar 

  6. Nebert DW, Jorge-Nebert L, Vesell ES (2003) Pharmacogenomics and “individualized drug therapy”: high expectations and disappointing achievements. Am J Pharmacogenomics 3(6):361–370

    Article  PubMed  Google Scholar 

  7. Tomalik-Scharte D, Lazar A, Fuhr U, Kirchheiner J (2008) The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J 8(1):4–15

    Article  PubMed  CAS  Google Scholar 

  8. Zhou J, Rossi JJ (2011) Aptamer-targeted RNAi for HIV-1 therapy. Methods Mol Biol 721:355–371

    Article  PubMed  CAS  Google Scholar 

  9. Thiel KW, Giangrande PH (2010) Intracellular delivery of RNA-based therapeutics using aptamers. Ther Deliv 1(6):849–861

    Article  PubMed  CAS  Google Scholar 

  10. Blagbrough IS, Zara C (2009) Animal models for target diseases in gene therapy—using DNA and siRNA delivery strategies. Pharm Res 26(1):1–18

    Article  PubMed  CAS  Google Scholar 

  11. Colombo R, Moll J (2008) Target validation to biomarker development: focus on RNA interference. Mol Diagn Ther 12(2):63–70

    PubMed  CAS  Google Scholar 

  12. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS (2004) Rational siRNA design for interference. Nat Biotechnol 22(3):326–330

    Article  PubMed  CAS  Google Scholar 

  13. Patzel V (2007) In silico selection of active siRNA. Drug Discov Today 12(3–4):139–148

    Article  PubMed  CAS  Google Scholar 

  14. Liao G, Zhang X, Clark DJ, Peltz G (2008) A genomic “roadmap” to “better” drugs. Drug Metab Rev 40(2):225–239

    Article  PubMed  CAS  Google Scholar 

  15. Yan Q (2008) The integration of personalized and systems medicine: bioinformatics support for pharmacogenomics and drug discovery. Methods Mol Biol 448:1–19

    Article  PubMed  CAS  Google Scholar 

  16. Sheiner LB (1997) Learning versus confirming in clinical drug development. Clin Pharmacol Ther 61:275–291

    Article  PubMed  CAS  Google Scholar 

  17. Simon R (2008) The use of genomics in clinical trial design. Clin Cancer Res 14(19):5984–5993

    Article  PubMed  Google Scholar 

  18. Ekins S, Mestres J, Testa B (2007) In silico pharmacology for drug discovery: applications to targets and beyond. Br J Pharmacol 152(1):21–37

    Article  PubMed  CAS  Google Scholar 

  19. Ekins S, Mestres J, Testa B (2007) In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Br J Pharmacol 152(1):9–20

    Article  PubMed  CAS  Google Scholar 

  20. Johnson AD, Wang D, Sadee W (2005) Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics. Pharmacol Ther 106(1):19–38

    Article  PubMed  CAS  Google Scholar 

  21. Fielden MR, Matthews JB, Fertuck KC, Halgren RG, Zacharewski TR (2002) In silico approaches to mechanistic and predictive toxicology: an introduction to bioinformatics for toxicologists. Crit Rev Toxicol 32(2):67–112

    Article  PubMed  CAS  Google Scholar 

  22. Noble D (2003) The future: putting Humpty-Dumpty together again. Biochem Soc Trans 31(Pt1):156–158

    PubMed  CAS  Google Scholar 

  23. Michelson S (2006) The impact of systems biology and biosimulation on drug discovery and development. Mol Biosyst 2(6–7):288–291

    Article  PubMed  CAS  Google Scholar 

  24. Guo Y, Shafer S, Weller P, Usuka J, Peltz G (2005) Pharmacogenomics and drug development. Pharmacogenomics 6(8):857–864

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chemical and Biomolecular Engineering, Vanderbilt University, VU Station B 351604, Nashville, TN, 37235, USA

    Aleš Prokop

  2. NanoDelivery International, s.r.o., 1327/113 Nádražní, 69141, Břeclav-Poštorná, Czech Republic

    Aleš Prokop

  3. Genomic Health Inc, 101 Galveston Dr, Redwood City, CA, 94063, USA

    Seth Michelson

Authors
  1. Aleš Prokop
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seth Michelson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aleš Prokop .

Rights and permissions

Reprints and permissions

Copyright information

© 2012 The Author(s)

About this chapter

Cite this chapter

Prokop, A., Michelson, S. (2012). Development: In Vivo Pharmacology—Systems Biology in Health and Disease II. In: Systems Biology in Biotech & Pharma. SpringerBriefs in Pharmaceutical Science & Drug Development, vol 2. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-2849-3_6

Download citation

  • DOI: https://doi.org/10.1007/978-94-007-2849-3_6

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-007-2848-6

  • Online ISBN: 978-94-007-2849-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation